Anatara Life Sciences (ASX:ANR) Investor Presentations Sydney and Melbourne
This month, Anatara's CEO, Steve Lydeamore will be presenting to investors at events in Sydney and Melbourne. We would like to extend to you the invitation to attend.
This month, Anatara's CEO, Steve Lydeamore will be presenting to investors at events in Sydney and Melbourne. We would like to extend to you the invitation to attend.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to report positive efficacy data from its in vitro Proof of Concept studies of its Gastrointestinal ReProgramming product. GaRP is a unique natural dietary supplement designed to restore and maintain a healthy human gut and microbiome.
Oventus Medical Ltd (ASX:OVN) is pleased to announce the Canadian launch of the O2Vent(R) Optima device which treats both the potentially fatal condition, obstructive sleep apnoea and snoring. The device launch in Canada follows the successful completion of a controlled market release, with early results demonstrating strong patient acceptance.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.
Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2018. The Company's cash position at the end of the quarter stood at $1.5m. The Company also had $4,500,000 in deposits with terms of greater than 90 days. Expenditure during the quarter was in line with forecast.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.
Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of Dr. David Brookes as Non-Executive Director and Chair of the Audit and Risk Committee, effective from 23 January 2019.